

Registered number: 11943477  
Charity number: 1185091

**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)  
**AUDITED TRUSTEES' REPORT AND FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

WEDNESDAY



\*ADBGH2E0\*

A10

11/09/2024

#84

COMPANIES HOUSE

**FOLLICULAR LYMPHOMA FOUNDATION**  
**(A company limited by guarantee)**

**CONTENTS**

	Page
<b>Reference and administrative details of the Company, its Trustees and advisers</b>	<b>1</b>
<b>Trustees' report</b>	<b>2</b>
<b>Independent auditors' report on the financial statements</b>	<b>10 - 13</b>
<b>Statement of financial activities</b>	<b>14</b>
<b>Balance sheet</b>	<b>15 - 16</b>
<b>Statement of cash flows</b>	<b>17</b>
<b>Notes to the financial statements</b>	<b>18 - 32</b>

**FOLLICULAR LYMPHOMA FOUNDATION**

**(A company limited by guarantee)**

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE COMPANY, ITS TRUSTEES AND ADVISERS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

<b>Trustees</b>	Lord J N Mendelsohn Lady N S Mendelsohn Lord R I Harrington P M V Thompson A Wong J J Burley Dr J W Simons
<b>Company registered number</b>	11943477
<b>Charity registered number</b>	1185091
<b>Registered office</b>	New Derwent House 69-73 Theobalds Road London WC1X 8TA
<b>Independent auditors</b>	Cooper Parry Group Limited Statutory Auditor 69-73 Theobalds Road London WC1X 8TA



## **FOLLICULAR LYMPHOMA FOUNDATION**

**(A company limited by guarantee)**

### **TRUSTEES' REPORT - FOR THE YEAR ENDED 31 DECEMBER 2023**

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the Year to 31 December 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

## **1. Objectives and activities**

Our mission is to help those with Follicular Lymphoma, a currently incurable blood cancer, to live well and get well by finding and funding the best research to find breakthroughs that will change how we understand and treat the condition. We provide Follicular Lymphoma focused information resources for patients and work to ensure patients' voices are at the heart of the search for better treatments and cure.

More specifically, the Charities objectives are restricted to the following:

**A.** To sponsor basic and translational research to assist in the development of better treatments and a cure for Follicular Lymphoma including sponsoring the establishment of an international challenge to scientific and clinical researchers to focus on prospective cures.

**B.** To support the promotion of the "patient voice", by supporting patient advocacy and education, the development of patient communities and evaluating the efficacy of patient reported outcomes on current treatments and side effects to assist clinicians and patients.

**C.** To improve health outcomes by way of stimulating research and evaluation of complementary conditions to supplement medical treatment.

## **2. Achievements**

### **Global FL Summit 'Joining Forces to Cure FL'**

Tel Aviv, Israel - January 2023

Our first international follicular lymphoma summit brought together a diverse group of world-class lymphoma experts, scientists, researchers, and representatives from the world's life sciences and biotech businesses. With a shared desire to move the field forward, participants discussed opportunities to enhance targeted immunotherapies. The importance of developing molecular markers, especially to define high-risk patients and the need for a deeper understanding of how transformation occurs in follicular lymphoma. All of which pushes us closer to a cure.

### **ICML Symposium 'What Will it Take to Cure FL?'**

Lugano, Switzerland – June 2023

We were thrilled to host our own satellite symposium at the International Conference on Malignant Lymphoma. Dr Mitchell Smith, Chief Medical Officer at the FLF, chaired the session, which focused on forward-looking presentations followed by a discussion with our expert panel of speakers: Dr Loretta Nastoupil, Dr Jessica Okosun, Dr Marco Ladetto, and Dr Ari Melnick. The stimulating programme spanned from basic biology to how to translate those learnings into the clinic for FL patients.

**Launched 'Your Support Hub'**, a dedicated online hub for individuals affected by follicular lymphoma, offering educational and lifestyle resources, patient stories, an FL-specific glossary, and more.



**Held educational webinars** which were received with enthusiasm and strong participation, underscoring their value to the community, and sparking demand for more.

**Partnered with the University of Pennsylvania's School of Clinical Medicine's** world renowned researchers as part of our Centres of Excellence (CoE) programme.

**Hosted a symposium at the International Conference on Malignant Lymphoma** on "What Will it Take to Cure Follicular Lymphoma?" which witnessed a robust turnout and significantly boosted our international visibility to shine a spotlight on follicular lymphoma.

**Collaborated with The Leukemia & Lymphoma Society (LLS)** in a strategic partnership to cure follicular lymphoma by combining expertise and resources.

**Jointly launched CURE FL Cycle 2 with LLS, 'LLS-FLF Research United to CURE FL Awards'**, funding up to 4 research grants totalling up to \$3.5m over 2-3 years, accelerating cutting-edge research in follicular lymphoma.

**Partnered with The Mark Foundation for Cancer Research** to unite lymphoma and biomarker technology experts, advancing novel approaches for follicular lymphoma.

**Gathered insights from over 700 patients** to enhance our understanding of biomarkers and ensure patient voices are heard. This provided invaluable insights to inform our biomarker discovery programme focus.

**Hosted our inaugural fundraising gala dinner** raising over £500,000 to advance our mission of curing follicular lymphoma.

**Developed a Biomarker Programme** set to fund 1-2 awards at approximately \$350k each, with a planned launch in 2024.

**Participated at ASH Annual Meeting**, the world's largest haematology conference, engaging with current and potential partners, and gaining insights from the many lymphoma-focused symposia.

### 3. Strategic report

The Follicular Lymphoma Foundation is an international effort to find and accelerate cures and speed the delivery of precision-based treatments for this little-known cancer.

The Foundation launched publicly in November 2019 and has been focused on developing its strategy and laying the framework for a hugely exciting programme of work.

None of this would have been possible without the extraordinary support of the hundreds of individuals who have donated to the Foundation to help achieve our goal.

#### 3.1 Charitable activities

##### 3.1.1 Strategy

Over the course of the year the FLF harnessed its global network to develop a strategic approach and framework. The Foundation created a programmatic plan based on two pillars:

- **Pillar 1:** The Patient & Precision Medicine Programme to harness the power of patients and the patient community in the development of cures and new precision medicine approaches
- **Pillar 2:** The Targeted Accelerated Research Programme to invest in only the most promising international FL research and clinical trials.



### 3.1.2 Partnerships

One of the Foundation's core working principles is to avoid duplication and bring added value to the field by forging partnerships to complement existing programmes, drive better outcomes and create impact.

Partnerships were established during this year with research institutions, other non-profits and commercial entities.

### 3.1.3 Information Provision and Public Awareness Raising

The launch of the FLF raised awareness of the disease with the general public and helped link people living with FL with sources of information and support.

As part of the launch the Foundation developed a new website as a trusted source of information FL patients and a more dedicated Patient Hub for FL Patients and families. This was the world's first website dedicated exclusively to Follicular Lymphoma.

## 3.2 Financial review

### 3.2.1 Financial position

The Financial accounts for the 12 months period show a surplus of £88,832 and the charity is well-positioned to increase its activities in the future.

### 3.2.2 Reserves policy

At 31 December 2023, unrestricted reserves were £1,103,336 and restricted reserves were £161,018.

The organisation operates with limited overheads. The Trustees have determined that the reserves target should be at the level of 3 months' expected expenditure. Budgeted expenditure in the 2024 financial year is just shy of £1.9m, and the Trustees have set a targeted reserves figure of £500k as at 31 December 2023.

The target for reserves in 2024 is to maintain a minimum coverage of six months' runway. This will ensure that all commitments and notices are addressed, providing the company with adequate time to implement any necessary emergency measures.

Currently, certain programmes, such as PMP, are partially on hold due to funding constraints. These programmes will be resumed once sufficient funding is secured and income streams and trends have stabilised.

## 3.3 Going concern

The Trustees consider that it is appropriate to prepare the financial statements on a going concern basis. The going concern assumption is based on an existing business plan and budget in place covering the period to December 2024. A new 3-year budget/forecast was drafted, and two annual forecasts planned each year, expenditure is micro analysed during these activities whilst planning long term.

In addition, the Trustees continue to investigate opportunities to enhance the long-term sustainability of the charity and identify those areas where the financial performance can be improved, with actions being taken to reduce the deficits. The performance of a highly skilled team of permanent employees demonstrates Follicular Lymphoma Foundation's commitment to the operation of the Charity as a going concern. As a result of these factors the Trustees consider the going concern basis to be appropriate.



### 3.4 Principal risks and uncertainties

The trustees have a duty to identify and review the risks to which the charity is exposed and to ensure appropriate controls are in place to provide reasonable assurance against fraud and error.

The trustees have assessed major risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to such major risks.

Procedures are in place to ensure compliance with health and safety of staff, volunteers, clients, and visitors to the organisation. The Charity has the appropriate level of insurance to meet its obligations in respect of employees and members of the public and otherwise has a business continuity plan to cover extreme eventualities.

### 3.5 Future plans

#### 3.5.1 Plans for the next 12 Months

*Our areas of focus:*

**Delivering impact through focused research.**

Closing the gaps in FL research and drug development through the dual approach of the provision 'evidence-based' FL information and investing in the most promising curative research.

Developing new treatments and cures to FL patients by creating a pathway with rapid 'bench-to-bedside' developments.

**Collaborating with the best.**

Relationships are key to the success of the charity. We will map existing and new opportunities for partnerships at an international level, building on critical relationship links with medical experts, scientific researchers, and philanthropic donors.

**Growing fundraising income.**

Raising funds is essential to ensuring our strategic medical programmes go ahead and that we have the financial resources available to carry out the necessary scientific research to find a cure. We strive to maintain and build fundraising streams where possible whilst also identifying new or different opportunities to drive fundraising.

#### 3.5.2 Precision Medicine Programme (PMP)

The Precision Medicine Programme (PMP) harnesses the power of the follicular lymphoma community to drive research and clinical advances.

**Accelerating progress towards a cure**

Our mission through the PMP is to unlock the potential of bespoke, precision medicine for FL patients, revolutionising treatment options and propelling us closer to finding a cure. By leveraging real-world data, including biological information, we seek to pioneer new avenues in FL research and drive biopharmaceutical and industry drug development.

**Understanding unique biology for personalised therapy**

At the core of the PMP is understanding each patient's distinct biology and utilising this knowledge to predict the most effective, tailored therapeutic options.

"The Precision Medicine Programme will be a unique resource of great value to researchers and ultimately to patients, enabling and accelerating biologic and clinical research and trials, and ultimately finding a cure for FL."

Dr Mitchell Smith, Chief Medical Officer.



#### Top research priorities

Working with partners worldwide, we identified key PMP objectives to address unmet follicular lymphoma needs:

- Understand disease heterogeneity
- Optimise treatment regimens and sequencing
- Profile and predict treatment toxicity
- Develop surrogate endpoints (for improved clinical trial design)
- Generate prospective real-world data

This project hinges on amassing the largest repository of information on FL, providing doctors, researchers, and patients with a newfound understanding of the disease. By leveraging this vast dataset, we can drive forward progress and transform the landscape of FL research and treatment.

### 3.5.3 Targeted Accelerated Research (TAR) programmes

One key area for the FLF is therapeutic development initiatives, which can accelerate advanced and translational research. To date, the progress in the treatment of FL has been frustratingly slow, with little funding and attention.

Our suite of Targeted Accelerated Research (TAR) initiatives aim to make curative therapies available to FL patients as soon as possible. Our TAR programmes enhance our progress towards our mission by investing in the highest calibre research promising immediate benefit to the patient (CURE FL Awards); creating strategic partnerships with top investigators and institutes around the world (Centres of Excellence); and ensuring we don't miss out on unique high-risk, high-reward opportunities (Opportunity Fund).

#### A. CURE FL Awards Programme

The CURE FL (Curative Research to Eliminate Follicular Lymphoma) Awards programme aims to stimulate scientific research into follicular lymphoma-targeted immunotherapy. It focuses on innovative research that aligns with patient interests and accelerates progress towards new treatments. A key feature of this approach is promoting collaboration and fostering deeper synergies among researchers to enhance capabilities and advancements in the field.

#### CURE FL Awards Cycle 1 (launched 2022)

A groundbreaking \$2 million programme which funds four innovative researchers exploring novel CAR-T cell therapies, or combinations, to enhance immunotherapy as a treatment option. The substantial advancements achieved throughout 2023 could significantly advance immunotherapies applied to follicular lymphoma, and even other diseases.

#### Meet the 2023 grantees

In collaboration with Milken CSP, we carefully selected proposals targeting key follicular lymphoma needs while prioritising patient interests and clinical application. After a thorough 5-month review involving experts and patients, we identified the most promising projects out of 20 worldwide proposals.

We are thrilled to introduce our first grantees and their exciting research areas. Each has been awarded up to \$500K over two years, beginning December 2022. This significant investment marks an initial stride toward our mission.

The Follicular Lymphoma Foundation is honoured to support the critical work of the following pioneering researchers who were selected as the inaugural CURE FL Awards grantees in December 2022:

- **Dr Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, US:** A new signal mechanism (HVEM/BTLA) abnormal in 90% of FL cases and important in the genesis of FL has been identified by Dr Wendel and his group. This makes HVEM/BTLA a high-value target specific to FL. CAR-T cells that attack all B cells are an exciting new treatment for FL. This study will use CAR-T in a different way, to specifically attack this FL-specific pathway. The goal is to have a clinical trial of these novel CAR-T cells open for patients by the end of the grant period.





- **Dr Joshua Brody, Icahn School of Medicine at Mount Sinai, US:** CAR-T cells are an excellent treatment for some patients with FL, but do not work for everyone. Dr Brody, an expert in immunotherapy of lymphoma, and his team have evidence that bystander cells that do not express the CAR-T target are one mechanism of CAR-T resistance, and that they may have a way to overcome this. Their study may well lead to a clinical trial of CAR-T given with a drug that will enhance the killing of these bystander cells, improving outcomes for patients.
- **Dr Wendy Béguélin, Weill Cornell Medicine, US: Dr Béguélin,** an expert in lymphoma biology, along with her clinical collaborators, will conduct trials combining epigenetic-targeted EZH2 inhibitors with immunotherapy (CAR-T or bispecific antibodies), or with apoptosis-targeted BCL2 inhibitors. Using unique FL mouse models and patient samples, she will study combinations of targeted therapies with immunotherapy, including impact on both FL B cells and its microenvironment. The plan is to define effective combinations to improve therapy in FL.
- **Dr Patricia Pérez-Galán, Fundació Clínic per a la Recerca Biomèdica, Spain:** Leading this Spanish group with extensive clinical experience developing CAR-T cell treatment for lymphoma. They will develop new generation dual-targeted CAR-T cells, cells that target not only lymphoma cells but also the surrounding microenvironment that helps keep FL cells alive. They hope to have a clinical trial of the best CAR-T ready by the end of the grant period.

#### **Accelerating progress and impact**

By allocating almost \$2 million over two years, the CURE FL Awards propel us closer to better treatments and a cure. We aim to elevate follicular lymphoma's significance in drug development and catalyse tailored therapies. Our goal is to bring hope, opportunities, and critical treatment insights to patients and clinicians.

#### **CURE FL Awards Cycle 2 (launched 2023)**

We are thrilled to collaborate with the Leukaemia & Lymphoma Society (LLS) for the second cycle of the CURE FL Awards, named the "LLS-FLF United to CURE FL Awards". Together, we will co-fund up to four research awards, with funding of up to \$3.5 million. This initiative focuses on innovative research projects targeting a cure for follicular lymphoma. The primary goal is to establish a rational treatment sequence that leads to curative outcomes for a broader group of patients. Many submissions have been received and following a comprehensive review process, the chosen researchers will be selected and announced in 2024.

#### **B. FLF Centres of Excellence (CoE)**

We are committed to forming collaborative partnerships with leading research institutions through our Centres of Excellence (CoE) programme. The primary focus is accelerating progress in T-cell-engaging therapies for follicular lymphoma, set to revolutionise patient care. We will do this by promoting knowledge exchange, breaking down academic barriers, and fostering an environment conducive to rapid advancements in clinical care and progress towards a cure.

#### **Sharing knowledge for rapid progress**

Collaboration and knowledge sharing are integral to the success of the CoE. We strive to break down academic silos, facilitating an open exchange of information and ideas. By fostering a collaborative environment, we create the conditions necessary for rapid advancements in clinical care for FL patients. Our commitment to sharing knowledge ensures that progress is accelerated and impactful across the entire programme.



Current collaborations:

**University of Pennsylvania (Upenn) School of Clinical Medicine**

Renowned for pioneering lymphoma research and a pivotal institution in CAR-T development. Our shared programme has intended funding of \$5 million over 3 years, with aims to validate trialling an approved bi-specific as a first-line treatment and a revolutionary new CAR-T at the second line.

**Dana-Farber Cancer Institute**

Internationally acclaimed for cancer research and treatment. Our partnership has enabled the establishment of a comprehensive programme focusing on FL, including the development of cutting-edge technologies to understand, monitor and attack FL.

**Sheba Centre and Sourasky Medical Centre**

Internationally acclaimed for cancer research and treatment. Our partnership has enabled the establishment of a comprehensive programme focusing on FL, including the development of cutting-edge technologies to understand, monitor and attack FL.

**C. Biomarker Discovery Programme**

Recognising that the lack of biomarkers to identify high-risk patients, guide treatment selection or serve as interim endpoints to evaluate treatment was a barrier to rapidly developing new treatments, the FLF embarked on a new initiative: The Biomarker Discovery Programme, in collaboration with the Mark Foundation for Cancer Research.

This programme aims to stimulate research that will eventually become state-of-the-art tools and methods for studying multiple biological factors (omics) and their analysis, removing obstacles to successful biomarker discovery and development and addressing critical questions in follicular lymphoma.

This initiative involves gaining insights from leading international scientists and experts to co-create a strategic roadmap and identify the most promising pathways to drive the follicular lymphoma biomarker field forward. During 2023, the key programme components included an investigators workshop, a global patient survey, and a dedicated patient roundtable discussion.

The Mark Foundation for Cancer Research and the FLF will co-fund through the ASPIRE Award program for projects focused on the development of potential biomarkers for various stages of the patient experience. This is expected to lay the foundations for translating the findings into clinical impact with awards anticipated to start towards the end of 2024.

### **3.6 Structure, governance, and management governing documents**

FLF is a private company limited by guarantee.

The company was established on 12 April 2019 under a Memorandum of Association which determines the objects and powers of the charitable company and is governed under its Articles of Association.

The charitable company was registered with the Charity Commission on 29 August 2019.

#### **3.6.1 Decision making**

The Board of Trustees meets 4 times per year and is responsible for the strategic direction and policy of the charity and for monitoring the management and outcomes of services. Board members are drawn from a variety of professional backgrounds relevant to the work of the charity.



### 3.6.2 Statement of trustees' responsibilities

The trustees (who are also the directors of Follicular Lymphoma Foundation for the purposes of company law) are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law of the United Kingdom

Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland"

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently.
- observe the methods and principles in the Charity SORP.
- make judgements and estimates that are reasonable and prudent.
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charitable company and to enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

So far as the trustees are aware:

- there is no relevant audit information of which the charitable company's auditors are unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

## 4. Auditors

The audit business of Haines Watts London LLP was acquired by Cooper Parry Group Limited on 14 November 2023. Haines Watts London LLP has resigned as auditor and Cooper Parry Group Limited has been appointed in its place. Cooper Parry Group Limited will be proposed for re-appointment at the forthcoming Annual General Meeting.

Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on 30-08-2024 and signed on the board's behalf by:

A handwritten signature in black ink, appearing to be "J N Mendelsohn", written over a dotted line.

Lord J N Mendelsohn - Trustee

**FOLLICULAR LYMPHOMA FOUNDATION**  
**(A company limited by guarantee)**

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION**

**Opinion**

We have audited the financial statements of Follicular Lymphoma Foundation (the 'charitable company') for the year ended 31 December 2023 which comprise the Statement of financial activities, the Balance sheet, the Statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2023 and of its incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

**Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

**Conclusions relating to going concern**

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

**FOLLICULAR LYMPHOMA FOUNDATION**  
**(A company limited by guarantee)**

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION**  
**(CONTINUED)**

**Other information**

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**Matters on which we are required to report by exception**

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Trustees' report is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

**Responsibilities of trustees**

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

**FOLLICULAR LYMPHOMA FOUNDATION**  
**(A company limited by guarantee)**

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION**  
**(CONTINUED)**

**Auditors' responsibilities for the audit of the financial statements**

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

We gained an understanding of the legal and regulatory framework applicable to the company and the industry in which it operates, and considered the risk of acts by the company that were contrary to applicable laws and regulations, including fraud. We discussed with the Directors the policies and procedures in place regarding compliance with laws and regulations. We discussed amongst the audit team the identified laws and regulations, and remained alert to any indications of non-compliance.

During the audit we focussed on laws and regulations which could reasonably be expected to give rise to a material misstatement in the financial statements, including, but not limited to, the Companies Act 2006 and UK tax legislation. Our tests included agreeing the financial statement disclosures to underlying supporting documentation and enquiries with management.

Our procedures in relation to fraud included but were not limited to: inquires of management whether they have any knowledge of any actual, suspected or alleged fraud, and discussions amongst the audit team regarding risk of fraud such as opportunities for fraudulent manipulation of financial statements. We determined that the principal risks related to posting manual journal entries to manipulate financial performance and management bias through judgements in accounting estimates. We also addressed the risk of management override of internal controls, including testing journals and evaluating whether there was evidence of bias by the directors that represented a risk of material misstatement due to fraud.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.


A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/auditorsresponsibilities](http://www.frc.org.uk/auditorsresponsibilities). This description forms part of our Auditors' report.

**FOLLICULAR LYMPHOMA FOUNDATION**  
**(A company limited by guarantee)**

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF FOLLICULAR LYMPHOMA FOUNDATION**  
**(CONTINUED)**

**Use of our report**

This report is made solely to the charitable Company's members, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charitable Company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable Company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.



**Jane Wills (Senior Statutory Auditor)**  
**for and on behalf of**  
**Cooper Parry Group Limited**  
Statutory Auditor  
69-73 Theobalds Road  
London  
WC1X 8TA

Date: 9 September 2024

**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)  
FOR THE YEAR ENDED 31 DECEMBER 2023**

	Note	Restricted funds 2023 £	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
<b>Income from:</b>					
Donations and legacies	3	295,857	1,766,378	2,062,235	2,184,639
Investments	4	-	6,419	6,419	1,619
<b>Total income</b>		<b>295,857</b>	<b>1,772,797</b>	<b>2,068,654</b>	<b>2,186,258</b>
<b>Expenditure on:</b>					
Raising funds	5	-	251,245	251,245	330,452
Charitable activities	6	141,417	1,587,158	1,728,575	2,079,711
<b>Total expenditure</b>		<b>141,417</b>	<b>1,838,403</b>	<b>1,979,820</b>	<b>2,410,163</b>
<b>Net income/(expenditure)</b>		<b>154,440</b>	<b>(65,606)</b>	<b>88,834</b>	<b>(223,905)</b>
Transfers between funds	14	22,979	(22,979)	-	-
<b>Net movement in funds</b>		<b>177,419</b>	<b>(88,585)</b>	<b>88,834</b>	<b>(223,905)</b>
<b>Reconciliation of funds:</b>					
Total funds brought forward		(16,401)	1,191,921	1,175,520	1,399,425
Net movement in funds		177,419	(88,585)	88,834	(223,905)
<b>Total funds carried forward</b>		<b>161,018</b>	<b>1,103,336</b>	<b>1,264,354</b>	<b>1,175,520</b>

**Continuing operations**

All income and expenditure has arisen from continuing activities.



**FOLLICULAR LYMPHOMA FOUNDATION**  
**(A company limited by guarantee)**  
**REGISTERED NUMBER: 11943477**

**BALANCE SHEET**  
**AS AT 31 DECEMBER 2023**

	Note	2023 £	2022 £
<b>Fixed assets</b>			
Tangible assets	11	4,999	7,033
		<u>4,999</u>	<u>7,033</u>
<b>Current assets</b>			
Debtors	12	83,846	57,766
Cash at bank and in hand		1,287,372	1,381,442
		<u>1,371,218</u>	<u>1,439,208</u>
Creditors: amounts falling due within one year	13	(111,863)	(270,721)
<b>Net current assets</b>		<u>1,259,355</u>	<u>1,168,487</u>
<b>Total assets less current liabilities</b>		<u>1,264,354</u>	<u>1,175,520</u>
<b>Net assets excluding pension asset</b>		<u>1,264,354</u>	<u>1,175,520</u>
<b>Total net assets</b>		<u><u>1,264,354</u></u>	<u><u>1,175,520</u></u>
<b>Charity funds</b>			
Restricted funds	14	161,018	(16,401)
Unrestricted funds	14	1,103,336	1,191,921
<b>Total funds</b>		<u><u>1,264,354</u></u>	<u><u>1,175,520</u></u>

The entity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the entity to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

However, an audit is required in accordance with section 144 of the Charities Act 2011.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

**FOLLICULAR LYMPHOMA FOUNDATION**

**(A company limited by guarantee)**

**REGISTERED NUMBER: 11943477**

**BALANCE SHEET (CONTINUED)**

**AS AT 31 DECEMBER 2023**

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:



.....  
**Lord J N Mendelsohn**  
Trustee

Date: 30-08-2024

**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)

**STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

	2023 £	2022 £
<b>Cash flows from operating activities</b>		
Cash generated from operations	(83,640)	(48,453)
<b>Cash flows from investing activities:</b>		
Purchase of tangible fixed assets	(448)	(4,600)
Interest received	6,419	1,619
<b>Net cash (used in)/provided by investing activities</b>	5,971	(2,981)
<b>Change in cash and cash equivalents in the year</b>	(77,669)	(51,434)
Cash and cash equivalents at the beginning of the year	1,365,041	1,416,475
<b>Cash and cash equivalents at the end of the year</b>	1,287,372	1,365,041

**FOLLICULAR LYMPHOMA FOUNDATION**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

**1. Accounting policies**

**1.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Follicular Lymphoma Foundation is a private company limited by guarantee, and a registered charity.

**1.2 Going concern**

The financial statements have been prepared on a going concern basis. The Trustees have reviewed and considered relevant information, including the annual budget and future cash flows in making their assessment. Based on these assessments, and the current resources available, the Trustees have concluded that they can continue to adopt the going concern basis in preparing the annual report and accounts.

**1.3 Income**

All income is recognised once the Company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

**1.4 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Company to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Company's objectives, as well as any associated support costs.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

**Governance costs**

Governance costs include costs of the preparation and examination of the statutory accounts, the costs of trustee meetings and the cost of any legal advice on governance matters.

**FOLLICULAR LYMPHOMA FOUNDATION**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

**1. Accounting policies (continued)**

**1.5 Taxation**

The Company is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the Company is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

**1.6 Tangible fixed assets and depreciation**

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Computer equipment	-	33%
--------------------	---	-----

**1.7 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**1.8 Cash at bank and in hand**

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**1.9 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Company anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

**1.10 Financial instruments**

The Company only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**FOLLICULAR LYMPHOMA FOUNDATION**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

**1. Accounting policies (continued)**

**1.11 Hire purchase and leasing commitments**

Rentals paid under operating leases are charged to the Statement of Financial Activities on a straight line basis over the period of the lease.

**1.12 Pensions**

The charitable company operates a defined contribution pension scheme. Contributions payable to the charitable company's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

**1.13 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

**1.14 Significant judgement and estimates**

Preparation of the financial statements requires management to make significant judgements and estimates in determining the carrying amounts of accruals and deferred income. Management makes assumptions of the effects of uncertain future events on those assets and liabilities at the balance sheet date. The management's estimates and assumptions are based on historical experience and expectation of future events and are reviewed periodically. This disclosure excludes uncertainty over future events and judgement in respect of measuring financial instruments.

Management do not consider there to be any material judgements or estimation and uncertainty requiring disclosure.

**2. Critical accounting estimates and areas of judgment**

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Company makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**3. Income from donations and legacies**

	<b>Restricted funds 2023 £</b>	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>
Donations	295,857	1,766,378	2,062,235

	<b>Unrestricted funds 2022 £</b>	<b>Total funds 2022 £</b>
Donations	2,184,639	2,184,639

**4. Investment income**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>
Deposit account interest	6,419	6,419

	<b>Unrestricted funds 2022 £</b>	<b>Total funds 2022 £</b>
Deposit account interest	1,619	1,619

**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**5. Expenditure on raising funds**

**Fundraising trading expenses**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>
Wages and salaries	116,082	116,082
Event costs	90,098	90,098
Fundraising fees	1,091	1,091
IT and support costs	138	138
Marketing and Communications	1,357	1,357
Allocation of general overheads	42,479	42,479
<b>Total 2023</b>	<b>251,245</b>	<b>251,245</b>

	<b>Unrestricted funds 2022 £</b>	<b>Total funds 2022 £</b>
Wages and salaries	86,929	86,929
Event Costs	14,220	14,220
Fundraising fees	12,950	12,950
IT and support costs	25,404	25,404
Marketing and Communications	8,233	8,233
Allocation of overheads	69,836	69,836
Consultancy	99,069	99,069
Travel	1,926	1,926
Investment management costs	11,887	11,887
<b>Total 2022</b>	<b>330,454</b>	<b>330,454</b>



**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**6. Analysis of expenditure on charitable activities**

**Summary by fund type**

	<b>Restricted funds 2023 £</b>	<b>Unrestricted funds 2023 £</b>	<b>Total 2023 £</b>
Direct costs	138,682	1,484,001	1,622,683
Support costs	2,735	103,157	105,892
<b>Total 2023</b>	<b>141,417</b>	<b>1,587,158</b>	<b>1,728,575</b>

	<b>Restricted funds 2022 £</b>	<b>Unrestricted funds 2022 £</b>	<b>Total 2022 £</b>
Direct costs	422,725	1,153,912	1,576,637
Support costs	-	503,074	503,074
<b>Total 2022</b>	<b>422,725</b>	<b>1,656,986</b>	<b>2,079,711</b>

**7. Analysis of expenditure by activities**

	<b>Activities undertaken directly 2023 £</b>	<b>Support costs 2023 £</b>	<b>Total funds 2023 £</b>
Direct costs	1,610,383	12,300	1,622,683
Support costs	-	105,892	105,892
<b>Total 2023</b>	<b>1,610,383</b>	<b>118,192</b>	<b>1,728,575</b>

**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**7. Analysis of expenditure by activities (continued)**

	Activities undertaken directly 2022 £	Support costs 2022 £	Total funds 2022 £
Direct costs	1,560,335	16,302	1,576,637
Support costs	-	503,074	503,074
<b>Total 2022</b>	<b>1,560,335</b>	<b>519,376</b>	<b>2,079,711</b>

**Analysis of support costs**

	Governance Costs 2023 £	Support Costs 2023 £	Total funds 2023 £
Marketing and Communications	-	34,588	34,588
Wages and salaries	-	185,981	185,981
Consultancy fees	-	36,242	36,242
IT and support costs	-	15,180	15,180
Travel and accommodation	-	339	339
Entertainment	-	122	122
Bank charges	-	1,583	1,583
Computer costs	-	15,496	15,496
Postage and stationery	-	572	572
Administrative expenses	-	4,003	4,003
Legal expenses	-	1,421	1,421
Depreciation	-	2,483	2,483
General expenses	-	884	884
Operating lease expenses	-	32,004	32,004
Event costs	-	680	680
Staff training	-	3,657	3,657
Recruitment costs	-	16,169	16,169
Allocation of general overheads	-	(267,796)	(267,796)
Foreign exchange losses	-	22,284	22,284
Governance costs	12,300	-	12,300
<b>Total 2023</b>	<b>12,300</b>	<b>105,892</b>	<b>118,192</b>

**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**7. Analysis of expenditure by activities (continued)**

**Analysis of support costs (continued)**

	Governance Costs 2022 £	Support Costs 2022 £	Total funds 2022 £
Marketing and Communications	-	94,417	94,417
Wages and Salaries	-	167,393	167,393
Consultancy	-	225,621	225,621
Travel and accommodation	-	10	10
Bank charges	-	1,119	1,119
Computer costs	-	13,811	13,811
Postage and stationery	-	1,175	1,175
Administrative expenses	-	41,689	41,689
Legal expenses	-	829	829
Depreciation	-	3,263	3,263
General expenses	-	153	153
Operating lease costs	-	24,070	24,070
Recruitment costs	-	4,384	4,384
Allocation of general overheads	-	(222,644)	(222,644)
Foreign exchange gain	-	(84,510)	(84,510)
Cure FL management costs	-	232,294	232,294
Governance costs	16,302	-	16,302
<b>Total 2022</b>	<b>16,302</b>	<b>503,074</b>	<b>519,376</b>

**8. Auditors' remuneration**

	2023 £	2022 £
Fees payable to the Company's auditor for the audit of the Company's annual accounts	12,000	15,056

**9. Staff costs**

The average number of persons employed by the Company during the year was as follows:

	2023 No.	2022 No.
Employees	7	5

**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**9. Staff costs (continued)**

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2023 No.	2022 No.
In the band £60,001 - £70,000	1	-
In the band £80,001 - £90,000	1	1
In the band £90,001 - £100,000	1	-
In the band £100,001 - £110,000	-	1
In the band £200,001 - £230,000	1	-

**10. Trustees' remuneration and expenses**

During the year, no Trustees received any remuneration or other benefits (2022 - £NIL).

**Donations from Trustees**

During the period, the total aggregate amount of unrestricted donations from Trustees was £71,700 (2022: £9,000)

During the year ended 31 December 2023, no Trustee expenses have been incurred (2022 - £NIL).

**11. Tangible fixed assets**

	<b>Computer equipment £</b>
<b>Cost or valuation</b>	
At 1 January 2023	14,816
Additions	448
At 31 December 2023	<u>15,264</u>
<b>Depreciation</b>	
At 1 January 2023	7,783
Charge for the year	2,482
At 31 December 2023	<u>10,265</u>

**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**11. Tangible fixed assets (continued)**

	<b>Computer equipment £</b>
<b>Net book value</b>	
At 31 December 2023	4,999
At 31 December 2022	7,033

**12. Debtors**

	<b>2023 £</b>	<b>2022 £</b>
<b>Due within one year</b>		
Trade debtors	73,256	50,000
Prepayments and accrued income	10,590	7,766
	<u>83,846</u>	<u>57,766</u>

**13. Creditors: Amounts falling due within one year**

	<b>2023 £</b>	<b>2022 £</b>
Overdraft due to negative restricted funds	-	16,401
Trade creditors	72,972	211,984
Other taxation and social security	24,723	23,579
Pension fund loan payable	1,580	850
Other creditors	-	706
Accruals and deferred income	12,588	17,201
	<u>111,863</u>	<u>270,721</u>

**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**14. Statement of funds**

**Statement of funds - current year**

	Balance at 1 January 2023 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 December 2023 £
<b>Unrestricted funds</b>					
Unrestricted funds	1,191,921	1,772,797	(1,838,403)	(22,979)	1,103,336
	Balance at 1 January 2023 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 December 2023 £
<b>Restricted funds</b>					
Maurice Wohl Charitable Foundation - towards Cure FL research	(16,401)	200,000	(93,413)	-	90,186
Mark Foundation for Cancer Research - towards Cure FL research	-	70,832	-	-	70,832
Bioinvent International AB & Novartis - towards Lugano event	-	20,275	(38,449)	18,174	-
Abbvie Ltd - towards Cure FL research	-	4,750	(9,555)	4,805	-
	(16,401)	295,857	(141,417)	22,979	161,018
<b>Total of funds</b>	1,175,520	2,068,654	(1,979,820)	-	1,264,354

**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**14. Statement of funds (continued)**

**Statement of funds - prior year**

	Balance at 1 January 2022 £	Expenditure £	Balance at 31 December 2022 £
<b>Unrestricted funds</b>			
Unrestricted funds	1,399,425	(207,504)	1,191,921
	<u>1,399,425</u>	<u>(207,504)</u>	<u>1,191,921</u>
<b>Restricted funds</b>			
Maurice Wohl Charitable Foundation - towards Cure FL research	-	(16,401)	(16,401)
	<u>-</u>	<u>(16,401)</u>	<u>(16,401)</u>
<b>Total of funds</b>	<u>1,399,425</u>	<u>(223,905)</u>	<u>1,175,520</u>

**15. Summary of funds**

**Summary of funds - current year**

	Balance at 1 January 2023 £	Income £	Expenditure £	Transfers in/out £	Balance at 31 December 2023 £
General funds	1,191,921	1,772,797	(1,838,403)	(22,979)	1,103,336
Restricted funds	(16,401)	295,857	(141,417)	22,979	161,018
	<u>1,175,520</u>	<u>2,068,654</u>	<u>(1,979,820)</u>	<u>-</u>	<u>1,264,354</u>

**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**15. Summary of funds (continued)**

**Summary of funds - prior year**

	Balance at 1 January 2022 £	Expenditure £	Balance at 31 December 2022 £
Designated funds	1,399,425	(207,504)	1,191,921
Restricted funds	-	(16,401)	(16,401)
	<u>1,399,425</u>	<u>(223,905)</u>	<u>1,175,520</u>

**16. Analysis of net assets between funds**

**Analysis of net assets between funds - current year**

	Restricted funds 2023 £	Unrestricted funds 2023 £	Total funds 2023 £
Tangible fixed assets	-	4,999	4,999
Current assets	161,018	1,210,200	1,371,218
Creditors due within one year	-	(111,863)	(111,863)
<b>Total</b>	<u>161,018</u>	<u>1,103,336</u>	<u>1,264,354</u>

**Analysis of net assets between funds - prior year**

	Restricted funds 2022 £	Unrestricted funds 2022 £	Total funds 2022 £
Tangible fixed assets	-	7,033	7,033
Current assets	(16,401)	1,455,609	1,439,208
Creditors due within one year	-	(270,721)	(270,721)
<b>Total</b>	<u>(16,401)</u>	<u>1,191,921</u>	<u>1,175,520</u>



**FOLLICULAR LYMPHOMA FOUNDATION**  
(A company limited by guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 31 DECEMBER 2023**

**17. Reconciliation of net movement in funds to net cash flow from operating activities**

	2023 £	2022 £
Net income/expenditure for the year (as per Statement of Financial Activities)	88,834	(223,905)
<b>Adjustments for:</b>		
Depreciation charges	2,482	3,263
Interest received	(6,419)	(1,619)
(Increase)/decrease in debtors	(26,080)	(34,992)
Increase/(decrease) in creditors	(142,457)	208,800
<b>Net cash used in operating activities</b>	<b>(83,640)</b>	<b>(48,453)</b>

**18. Analysis of cash and cash equivalents**

	2023 £	2022 £
Cash in hand	1,287,372	1,381,442
Deficit in restricted reserve	-	(16,401)
<b>Total cash and cash equivalents</b>	<b>1,287,372</b>	<b>1,365,041</b>

**19. Analysis of changes in net debt**

	At 1 January 2023 £	Cash flows £	At 31 December 2023 £
Cash at bank and in hand	1,381,442	(94,070)	1,287,372
Debt due within 1 year	(17,251)	15,671	(1,580)
	<b>1,364,191</b>	<b>(78,399)</b>	<b>1,285,792</b>

**FOLLICULAR LYMPHOMA FOUNDATION**  
**(A company limited by guarantee)**

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 31 DECEMBER 2023**

**20. Members' liability**

The charitable company is limited by guarantee and has no share capital. In the event of the charitable company being wound-up, the liability in respect of the guarantee is limited to £10 per member of the charitable company during the time they are a member or within one year of ceasing to be a member, as stated in the Memorandum and Articles of Association.

**21. Related party transactions**

There were no further related party transactions other than the trustees' donations disclosed in note 10 for the year ended 31 December 2023.